ResearcherFudan UniversityActive in the last 2 years

Liang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8529-8886; OpenAlex author ID A5050333645. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. Last author DOI 10.3724/abbs.2023288 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jinbin Jia · 1 shared paper, 2024 · strength 0.23
- Paper Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. DOI 10.3724/abbs.2023288 ↗
Zheng Zhang · 1 shared paper, 2024 · strength 0.23
- Paper Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. DOI 10.3724/abbs.2023288 ↗
Wenquan Wang · 1 shared paper, 2024 · strength 0.23
- Paper Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. DOI 10.3724/abbs.2023288 ↗
Zijin Xu · 1 shared paper, 2024 · strength 0.23
- Paper Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. DOI 10.3724/abbs.2023288 ↗
Yun Jin · 1 shared paper, 2024 · strength 0.23
- Paper Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. DOI 10.3724/abbs.2023288 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.